search
Back to results

Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia (HIATUS)

Primary Purpose

Large Hiatal Hernia

Status
Not yet recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Laparoscopic hiatal hernia repair
Sponsored by
University Hospital, Bordeaux
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Large Hiatal Hernia focused on measuring Large Hiatal Hernia, Recurrence, Surgery, Biosynthetic absorbable mesh

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Patient undergoing laparoscopic primary repair for symptomatic LHH. LHH is defined as a hiatal hernia larger than 5 cm in axial length as diagnosed at barium series and/or CT-scan with contrast swallow and/or CT-scan with contrast injection with axial reconstruction. Symptomatic hiatal hernia: heartburn and/or regurgitation and/or epigastric pain and/or dysphagia and/or anemia (if exclusion of other origin); Patient aged ≥ 18 years; Patient affiliated to a social security system or beneficiary of the same; Free written informed consent signed by the participant and the investigator (no later than the inclusion day and before performing any examination required for the study). Exclusion Criteria: Patient undergoing reoperation for recurrent LHH repair; Emergency presentation needing an operation in a delay <6 hours; Asymptomatic hiatal hernia; American anesthesiologist score >3; Recurrent hiatal hernia and previous surgical interventions involving gastroesophageal junction; Brachyesophagus defined as the impossibility to achieve an intraabdominal length of the esophagus of at least 3cm after reduction of hernia contents and complete dissection and resection of the hernia sac; Previous major upper gastrointestinal surgery; Inability to perform primary closure of the crura; Pregnant or breast-feeding woman; Persons deprived of liberty or under guardianship or incapable of giving consent; Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule, as assessed by investigator.

Sites / Locations

  • CH de la Côte Basque
  • Hôpital Jean Minjoz, CHRU de Besançon
  • Hôpital Cavale blanche, CHRU de Brest
  • Hôpital Côte de nacre, CHU Caen Normandie
  • Hôpital Estang
  • Hôpital Louis-Mourier, AP-HP
  • Hôpital Nord, CHU de Grenoble
  • Hôpital Claude Huriez, CHRU de Lille
  • Polyclinique du bois, Hôpital privé Le Bois
  • Hôpital Dupuytren 1, CHU de Limoges
  • Hôpital de la Croix-Rousse, HCL
  • Hôpital Saint Eloi, CHU de Montpellier
  • Hôpital Hôtel Dieu, CHU de Nantes
  • Hôpital Archet, CHU de Nice
  • Hôpital Saint-Louis, AP-HP
  • Hôpital Saint-Antoine, AP-HP
  • DMU SAPERE, CHU Pitié-Salpêtrière APHP
  • Institut Mutualiste Montsouris
  • Hôpital Bichat, AP-HP
  • Hôpital du Haut Lévêque
  • Hôpital Jean-Bernard, CHU de Poitiers
  • CH René-Dubos
  • CHU de Rennes, Site PONTCHAILLOU
  • Hôpital Charles Nicolle, CHU de Rouen
  • Hôpital Felix-Guyon, CHU de la Réunion
  • Hôpital Rangueil, CHU de Toulouse

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Biosynthetic absorbable mesh

No biosynthetic absorbable mesh

Arm Description

Patients who have undergone hiatal surgery with use of a biosynthetic absorbable mesh

Patients who have undergone hiatal surgery without use of a biosynthetic absorbable mesh

Outcomes

Primary Outcome Measures

Number of Large Hiatal Hernia recurrence
Radiologic recurrence will be identified at 24 months by an experienced radiologist blinded to the result of randomization and defined as the presence of any abdominal content located above the level of the diaphragm on CT-scan.

Secondary Outcome Measures

Evaluation of Quality of life (QoL) by GIQLI,
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by GIQLI,
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by GIQLI,
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by GIQLI,
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by GIQLI,
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by SF36 questionnaire
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by SF36 questionnaire
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by SF36 questionnaire
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by SF36 questionnaire
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by SF36 questionnaire
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-5D-5L
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-5D-5L
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-5D-5L
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-5D-5L
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-5D-5L
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Evaluation of Quality of life (QoL) by EQ-VAS
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Evaluation of Quality of life (QoL) by EQ-VAS
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Evaluation of Quality of life (QoL) by EQ-VAS
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Evaluation of Quality of life (QoL) by EQ-VAS
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Evaluation of Quality of life (QoL) by EQ-VAS
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
measurement of fever
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
measurement of fever
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
measurement of fever
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
measuring fever with a thermometer
measurement of weight
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
measurement of weight
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
measurement of weight
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
measurement of weight
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
measurement of weight
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
measurement of blood pressure
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
measurement of blood pressure
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
measurement of blood pressure
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
measurement of blood pressure
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
measurement of blood pressure
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.

Full Information

First Posted
December 30, 2022
Last Updated
May 16, 2023
Sponsor
University Hospital, Bordeaux
search

1. Study Identification

Unique Protocol Identification Number
NCT05867225
Brief Title
Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia
Acronym
HIATUS
Official Title
Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia: a Multicenter, Randomized, Parallel-group, Evaluator Blinded, Phase III Clinical Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2023 (Anticipated)
Primary Completion Date
July 1, 2025 (Anticipated)
Study Completion Date
July 1, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Bordeaux

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The large hiatal hernia (LHH) now represents approximately 50% of laparoscopic antireflux surgical practice. In a non-comparative retrospective study of 399 patients operated for LHH with onlay patch of a bioprosthetic absorbable (Gore® Bio-A® HH0710) mesh with a mean follow-up of 44 months, 16% had a symptomatic recurrence with 7,9% requiring reoperation, one patient had oesophageal stenosis. No comparative effectiveness data exist to date. Hypothesis: the incidence of postoperative hiatus hernia would be reduced by the addition of biosynthetic absorbable mesh reinforcement to a standardized suture repair technique, as compared to laparoscopic repair without mesh, without increasing the risk of complications. The main objective is to compare the radiologic recurrence rate at 2 years between standardized herniorrhaphy with onlay biosynthetic absorbable mesh repair versus standardized herniorrhaphy with no mesh in symptomatic LHH.
Detailed Description
The large hiatal hernia (LHH) now represents approximately 50% of laparoscopic antireflux surgical practice. Aging of the population and improvement of perioperative management may suggest that the number of these interventions will increase in the next few years. However, recurrence is common and has been described in up to 30% of patients who have undergone laparoscopic repair after a median follow up of 24 months. The use of mesh reinforcement has been suggested to help preventing recurrence after LHH repair with non-absorbable and absorbable mesh. In a non-comparative retrospective study of 399 patients operated for LHH with onlay patch of a bioprosthetic absorbable (Gore® Bio-A® HH0710) mesh with a mean follow-up of 44 months, 16% had a symptomatic recurrence with 7,9% requiring reoperation, one patient had oesophageal stenosis. No comparative effectiveness data exist to date. Hypothesis: the incidence of postoperative hiatus hernia would be reduced by the addition of biosynthetic absorbable mesh reinforcement to a standardized suture repair technique, as compared to laparoscopic repair without mesh, without increasing the risk of complications. The main objective is to compare the radiologic recurrence rate at 2 years between standardized herniorrhaphy with onlay biosynthetic absorbable mesh repair versus standardized herniorrhaphy with no mesh in symptomatic LHH. The secondary objectives are : To compare the improvement of specific symptoms between two arms; To compare the Quality of life; To compare the complication rate and thecomplication severity according to the Clavien-Dindo classification; To assess the cost-effectiveness of standardized herniorrhaphy with onlay biosynthetic absorbable mesh repair as compared to standardized herniorrhaphy with no mesh, in symptomatic LHH, at 2 years, from the French Healthcare system point of view. The expected benefits are : for the patient the diminution of LHH recurrence rate, quality of life improvement for Public health: Reducing the rate of reoperation for LHH; Reduction of healthcare costs due to a decrease in proton pump consumption and surgical re-interventions; The use of a synthetic bioprosthesis in laparoscopic surgery could be largely recommended and reimbursed either through the tariff related to the hospital stay (DRG tariff) or in additionto this tariff; Long term follow-up up to 5 years, could be obtained thanks to the use of French health insurance databases.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Large Hiatal Hernia
Keywords
Large Hiatal Hernia, Recurrence, Surgery, Biosynthetic absorbable mesh

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
256 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Biosynthetic absorbable mesh
Arm Type
Experimental
Arm Description
Patients who have undergone hiatal surgery with use of a biosynthetic absorbable mesh
Arm Title
No biosynthetic absorbable mesh
Arm Type
Sham Comparator
Arm Description
Patients who have undergone hiatal surgery without use of a biosynthetic absorbable mesh
Intervention Type
Procedure
Intervention Name(s)
Laparoscopic hiatal hernia repair
Intervention Description
laparoscopic hiatal hernia repair has replaced the traditional laparotomic or thoracotomic approach, and has resulted in a reduction of length of hospital stay and morbidity, and increased patients' acceptance
Primary Outcome Measure Information:
Title
Number of Large Hiatal Hernia recurrence
Description
Radiologic recurrence will be identified at 24 months by an experienced radiologist blinded to the result of randomization and defined as the presence of any abdominal content located above the level of the diaphragm on CT-scan.
Time Frame
Month 24
Secondary Outcome Measure Information:
Title
Evaluation of Quality of life (QoL) by GIQLI,
Description
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Time Frame
Day 0
Title
Evaluation of Quality of life (QoL) by GIQLI,
Description
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Time Frame
Month 1
Title
Evaluation of Quality of life (QoL) by GIQLI,
Description
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Time Frame
Month 6
Title
Evaluation of Quality of life (QoL) by GIQLI,
Description
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Time Frame
Month 12
Title
Evaluation of Quality of life (QoL) by GIQLI,
Description
GIQLI questionnaire includes 36 items relating to symptoms, physical status, emotions, social problems, and the effect of medical treatments. The score is between 0 and 144. The higher is the score, better is the quality of life.
Time Frame
Month 24
Title
Evaluation of Quality of life (QoL) by SF36 questionnaire
Description
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Time Frame
Day 0
Title
Evaluation of Quality of life (QoL) by SF36 questionnaire
Description
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Time Frame
Month 1
Title
Evaluation of Quality of life (QoL) by SF36 questionnaire
Description
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Time Frame
Month 6
Title
Evaluation of Quality of life (QoL) by SF36 questionnaire
Description
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Time Frame
Month 12
Title
Evaluation of Quality of life (QoL) by SF36 questionnaire
Description
SF36 questionnaire consists of 36 items, including eight health-related scales: general physical condition, physical health role limitations, body pain, general health perception, vitality, social functioning, health role limitations psychic. The score is between 36 and 180. The higher is the score, better is the quality of life.
Time Frame
Month 24
Title
Evaluation of Quality of life (QoL) by EQ-5D-5L
Description
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Time Frame
Day 0
Title
Evaluation of Quality of life (QoL) by EQ-5D-5L
Description
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Time Frame
Month 1
Title
Evaluation of Quality of life (QoL) by EQ-5D-5L
Description
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Time Frame
Month 6
Title
Evaluation of Quality of life (QoL) by EQ-5D-5L
Description
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Time Frame
Month 12
Title
Evaluation of Quality of life (QoL) by EQ-5D-5L
Description
EQ-5D-5L questionnaire comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The score is between 5 and 25. The lower is the score, better is the quality of life.
Time Frame
Month 24
Title
Evaluation of Quality of life (QoL) by EQ-VAS
Description
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Time Frame
Day 0
Title
Evaluation of Quality of life (QoL) by EQ-VAS
Description
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Time Frame
Month 1
Title
Evaluation of Quality of life (QoL) by EQ-VAS
Description
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Time Frame
Month 6
Title
Evaluation of Quality of life (QoL) by EQ-VAS
Description
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Time Frame
Month 12
Title
Evaluation of Quality of life (QoL) by EQ-VAS
Description
EQ-VAS questionnaire asks patients to indicate their overall health on a vertical visual analogue scale, ranging from "worst possible" (score 0) to "best possible" health (score 100).
Time Frame
Month 24
Title
measurement of fever
Description
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
Time Frame
Month 1
Title
measurement of fever
Description
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
Time Frame
Month 6
Title
measurement of fever
Description
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
Time Frame
Month 12
Title
measuring fever with a thermometer.Temperature is measured in degree Celsius (°C), between 34,7 and 40 °C.
Description
measuring fever with a thermometer
Time Frame
Month 24
Title
measurement of weight
Description
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
Time Frame
Day 0
Title
measurement of weight
Description
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
Time Frame
Month 1
Title
measurement of weight
Description
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
Time Frame
Month 6
Title
measurement of weight
Description
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
Time Frame
Month 12
Title
measurement of weight
Description
Measuring weight loss with a scale.The unit is kilogram. Weight change is between 30 and 150
Time Frame
Month 24
Title
measurement of blood pressure
Description
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
Time Frame
Day 0
Title
measurement of blood pressure
Description
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
Time Frame
Month 1
Title
measurement of blood pressure
Description
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
Time Frame
Month 6
Title
measurement of blood pressure
Description
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
Time Frame
Month 12
Title
measurement of blood pressure
Description
Systolic and diastolic blood pressure are measured in millimeter of mercury (mm Hg). Systolic blood pressure is between 70 and 220 mm Hg. Diastolic blood pressure is between 20 and 160 mm Hg.
Time Frame
Month 24

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patient undergoing laparoscopic primary repair for symptomatic LHH. LHH is defined as a hiatal hernia larger than 5 cm in axial length as diagnosed at barium series and/or CT-scan with contrast swallow and/or CT-scan with contrast injection with axial reconstruction. Symptomatic hiatal hernia: heartburn and/or regurgitation and/or epigastric pain and/or dysphagia and/or anemia (if exclusion of other origin); Patient aged ≥ 18 years; Patient affiliated to a social security system or beneficiary of the same; Free written informed consent signed by the participant and the investigator (no later than the inclusion day and before performing any examination required for the study). Exclusion Criteria: Patient undergoing reoperation for recurrent LHH repair; Emergency presentation needing an operation in a delay <6 hours; Asymptomatic hiatal hernia; American anesthesiologist score >3; Recurrent hiatal hernia and previous surgical interventions involving gastroesophageal junction; Brachyesophagus defined as the impossibility to achieve an intraabdominal length of the esophagus of at least 3cm after reduction of hernia contents and complete dissection and resection of the hernia sac; Previous major upper gastrointestinal surgery; Inability to perform primary closure of the crura; Pregnant or breast-feeding woman; Persons deprived of liberty or under guardianship or incapable of giving consent; Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol or follow-up schedule, as assessed by investigator.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Caroline Gronnier, MD, PhD
Phone
+ 33 5 57 65 60 05
Email
caroline.gronnier@chu-bordeaux.fr
First Name & Middle Initial & Last Name or Official Title & Degree
Valérie Aurillac-Lavignolle
Phone
+33 5 57 82 24 77
Email
valerie.aurillac@chu-bordeaux.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Caroline Gronnier, MD, PhD
Organizational Affiliation
University Hospital, Bordeaux
Official's Role
Principal Investigator
Facility Information:
Facility Name
CH de la Côte Basque
City
Bayonne
ZIP/Postal Code
64100
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laura Etchechoury, MD
Phone
+335.59.44.35.02
Email
atunita64@hotmail.com
First Name & Middle Initial & Last Name & Degree
Laura Etchechoury, MD
Facility Name
Hôpital Jean Minjoz, CHRU de Besançon
City
Besançon
ZIP/Postal Code
25000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pierre Mathieu, MD
Phone
+333 81 66 83 22
Email
pmathieu@chu-besancon.fr
First Name & Middle Initial & Last Name & Degree
Pierre Mathieu, MD
Facility Name
Hôpital Cavale blanche, CHRU de Brest
City
Brest
ZIP/Postal Code
29000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jérémie Théréaux, MD
Phone
+332 98 34 72 35
Email
jeremie.thereaux@chu-brest.fr
First Name & Middle Initial & Last Name & Degree
Jérémie Théréaux, MD
Facility Name
Hôpital Côte de nacre, CHU Caen Normandie
City
Caen
ZIP/Postal Code
14000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Gil Lebreton, MD
Phone
+332.31.06.32.21
Email
lebreton-g@chu-caen.fr
First Name & Middle Initial & Last Name & Degree
Gil Lebreton, MD
Facility Name
Hôpital Estang
City
Clermont-Ferrand
ZIP/Postal Code
63000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Olivier Antomarchi, MD
Email
oantomarchi@chu-clermontferrand.fr
First Name & Middle Initial & Last Name & Degree
Olivier Antomarchi, MD
Facility Name
Hôpital Louis-Mourier, AP-HP
City
Colombes
ZIP/Postal Code
92700
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
David Moszkowicz, MD
Phone
+331 47 60 68 00
Email
david.moszkowicz@aphp.fr
First Name & Middle Initial & Last Name & Degree
David Moszkowicz, MD
Facility Name
Hôpital Nord, CHU de Grenoble
City
La Tronche
ZIP/Postal Code
38700
Country
France
Facility Name
Hôpital Claude Huriez, CHRU de Lille
City
Lille
ZIP/Postal Code
59000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Guillaume Piessen, MD, PhD
Phone
+333 20 44 55 06
Email
guillaume.piessen@chru-lille.fr
First Name & Middle Initial & Last Name & Degree
Guillaume Piessen, MD, PhD
Facility Name
Polyclinique du bois, Hôpital privé Le Bois
City
Lille
ZIP/Postal Code
5900
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Briez, MD
Phone
+333.20.38.62.26
Email
brieznico@msn.com
First Name & Middle Initial & Last Name & Degree
Nicolas Briez, MD
Facility Name
Hôpital Dupuytren 1, CHU de Limoges
City
Limoges
ZIP/Postal Code
87000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Muriel Mathonnet, MD, PhD
Phone
+335 55 05 67 13
Email
mathonnet@unilim.fr
First Name & Middle Initial & Last Name & Degree
Muriel Mathonnet, MD, PhD
Facility Name
Hôpital de la Croix-Rousse, HCL
City
Lyon
ZIP/Postal Code
69000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Salim Mezoughi, MD
Phone
+334.72.07.11.00
Email
salim.mezoughi@chu-lyon.fr
First Name & Middle Initial & Last Name & Degree
Salim Mezoughi, MD
Facility Name
Hôpital Saint Eloi, CHU de Montpellier
City
Montpellier
ZIP/Postal Code
34000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Michel Fabre, MD, PhD
Phone
+334.67.33.70.72
Email
jm-fabre@chu-montpellier.fr
First Name & Middle Initial & Last Name & Degree
Jean-Michel Fabre, MD, PhD
Facility Name
Hôpital Hôtel Dieu, CHU de Nantes
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Claire Blanchard, MD
Phone
+332 76 64 37 98
Email
Claire.BLANCHARD@chu-nantes.fr
First Name & Middle Initial & Last Name & Degree
Claire Blanchard, MD
Facility Name
Hôpital Archet, CHU de Nice
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Antonio Ianelli, MD, PhD
Phone
+334.97.07.28.00
Email
IANNELLI.A@chu-nice.fr
First Name & Middle Initial & Last Name & Degree
Antonio Ianelli, MD, PhD
Facility Name
Hôpital Saint-Louis, AP-HP
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Hôpital Saint-Antoine, AP-HP
City
Paris
ZIP/Postal Code
75012
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuel Attal, MD
Phone
+331.49.28.25.47
Email
emmanuelattal@orange.fr
First Name & Middle Initial & Last Name & Degree
Emmanuel Attal, MD
Facility Name
DMU SAPERE, CHU Pitié-Salpêtrière APHP
City
Paris
ZIP/Postal Code
75013
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Laurent Genser, MD
Phone
+331 42 17 56 44
Email
laurent.genser@aphp.fr
First Name & Middle Initial & Last Name & Degree
Laurent Genser, MD
Facility Name
Institut Mutualiste Montsouris
City
Paris
ZIP/Postal Code
75014
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Stéphane Bonnet, MD, PhD
Phone
+331 56 61 67 12
Email
stephane.bonnet@imm.fr
First Name & Middle Initial & Last Name & Degree
Stéphane Bonnet, MD, PhD
Facility Name
Hôpital Bichat, AP-HP
City
Paris
ZIP/Postal Code
75018
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Simon Msika, MD, PhD
Phone
+331.40.25.69.03
Email
simon.msika@aphp.fr
First Name & Middle Initial & Last Name & Degree
Simon Msika, MD, PhD
Facility Name
Hôpital du Haut Lévêque
City
Pessac
ZIP/Postal Code
33600
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Caroline Gronnier, MD, PhD
Phone
+335 57 65 60 05
Email
caroline.gronnier@chu-bordeaux.fr
First Name & Middle Initial & Last Name & Degree
Caroline Gronnier, MD, PhD
Facility Name
Hôpital Jean-Bernard, CHU de Poitiers
City
Poitiers
ZIP/Postal Code
86000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jean-Pierre Faure, MD, PhD
Phone
+335.49.44.43.21
Email
j.p.faure@chu-poitiers.fr
First Name & Middle Initial & Last Name & Degree
Jean-Pierre Faure, MD, PhD
Facility Name
CH René-Dubos
City
Pontoise
ZIP/Postal Code
95000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nelson Trelles, MD
Phone
+331.30.75.40.22
Email
nelsontrelles@gmail.com
First Name & Middle Initial & Last Name & Degree
Nelson Trelles, MD
Facility Name
CHU de Rennes, Site PONTCHAILLOU
City
Rennes
ZIP/Postal Code
35000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Damien Bergeat, MD
Phone
+332 99 28 43 21
Email
damien.bergeat@chu-rennes.fr
First Name & Middle Initial & Last Name & Degree
Damien Bergeat, MD
Facility Name
Hôpital Charles Nicolle, CHU de Rouen
City
Rouen
ZIP/Postal Code
76000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Emmanuel Huet, MD
Phone
+332.32.88.85.72
Email
emmanuel.huet@chu-rouen.fr
First Name & Middle Initial & Last Name & Degree
Emmanuel Huet, MD
Facility Name
Hôpital Felix-Guyon, CHU de la Réunion
City
Saint Paul
ZIP/Postal Code
97415
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Radwan Kassir, MD
Phone
+332 62 90 54 60
Email
radwankassir42@hotmail.fr
First Name & Middle Initial & Last Name & Degree
Radwan Kassir, MD
Facility Name
Hôpital Rangueil, CHU de Toulouse
City
Toulouse
ZIP/Postal Code
31000
Country
France
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Nicolas Carrere, MD
Phone
+335.61.32.21.88
Email
carrere.n@chu-toulouse.fr
First Name & Middle Initial & Last Name & Degree
Nicolas Carrere, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Onlay Synthetic Bioabsorbable Mesh Herniorrhaphy Versus Herniorrhaphy Only in the Primary Treatment of Large Hiatal Hernia

We'll reach out to this number within 24 hrs